World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
29241
World Ranking
10163
National Ranking
560

Overview

Ulrich Keilholz is affiliated with Charité - University Medicine Berlin in Germany. Their research primarily spans the field of medicine, with a focus on oncology and related subfields. The main areas of study include oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and pathology and forensic medicine.

Keilholz's work covers diverse topics within cancer science. Key research themes include:

  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Cells and Metastasis
  • Head and Neck Cancer Studies
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Treatments and Studies

They have contributed to the scientific community through numerous publications, frequently appearing in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, bioRxiv (Cold Spring Harbor Laboratory), and Cancer Research.

Some of the recent papers that include Ulrich Keilholz as an author are:

  • ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee, 2020, Annals of Oncology

Among notable publications co-authored alongside scientists such as Damian Rieke, Frederick Klauschen, Konrad Klinghammer, Stefan Fröhling, and Ulrich Keller, Keilholz's research contributions stand within high-impact clinical and translational oncology topics.

Frequent co-authors include:

  • Damian Rieke
  • Frederick Klauschen
  • Konrad Klinghammer
  • Stefan Fröhling
  • Ulrich Keller

Frequent publication venues with contributions from Keilholz include:

  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research

Best Publications

  • Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    Ezra E W Cohen;Denis Soulières;Christophe Le Tourneau;Christophe Le Tourneau;Christophe Le Tourneau;José Dinis

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

    Alexander M. M. Eggermont;Stefan Suciu;Mario Santinami;Alessandro Testori

  • Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

    Claus Garbe;Thomas K. Eigentler;Ulrich Keilholz;Axel Hauschild

  • Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    R. Dummer;A. Hauschild;N. Lindenblatt;G. Pentheroudakis

  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Jean Pascal H Machiels;Robert I. Haddad;Jérôme Fayette;Lisa F. Licitra

  • Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

    Alexander M. M. Eggermont;Stefan Suciu;Rona Mackie;Wlodzimierz Ruka

  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

    Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich

  • A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

    Ulrich Keilholz;Anne Letsch;Antonia Busse;Anne Marie Asemissen

  • CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

    Carmen Scheibenbogen;Anne Letsch;Eckhard Thiel;Alexander Schmittel

  • A clinical development paradigm for cancer vaccines and related biologics.

    Axel Hoos;Giorgio Parmiani;Kristen Hege;Mario Sznol

  • Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Stefan Suciu;Alessandro Testori;Mario Santinami

  • Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

    Moritz Schütte;Thomas Risch;Nilofar Abdavi-Azar;Karsten Boehnke

  • Circulating tumor cells: the 'leukemic phase' of solid cancers.

    Simone Mocellin;Ulrich Keilholz;Carlo Riccardo Rossi;Donato Nitti

  • Natural T cell immunity against cancer.

    Dirk Nagorsen;Carmen Scheibenbogen;Francesco M. Marincola;Anne Letsch

  • Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

    Ulrich Keilholz;Christian Conradt;Sewa S Legha;David Khayat

  • Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

    Wim H J Kruit;Stefan Suciu;Brigitte Dreno;Laurent Mortier

  • Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas

    R. Max;R.R.C.M. Gerritsen;P.T.G.A. Nooijen;S.L. Goodman

  • Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial

    Henrik Schmidt;Stefan Suciu;Cornelis J.A. Punt;Martin Gore

  • Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

    Dan P. Zandberg;Alain P. Algazi;Antonio Jimeno;James S. Good

Frequent Co-Authors

Eckhard Thiel
Eckhard Thiel Charité - University Medicine Berlin
Carmen Scheibenbogen
Carmen Scheibenbogen Charité - University Medicine Berlin
Alexander M.M. Eggermont
Alexander M.M. Eggermont Institut Gustave Roussy
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Stefan Suciu
Stefan Suciu European Organisation for Research and Treatment of Cancer
Reinhard Dummer
Reinhard Dummer University of Zurich
Axel Hauschild
Axel Hauschild Kiel University
Reinhold Schäfer
Reinhold Schäfer Charité - University Medicine Berlin
Claus Garbe
Claus Garbe University of Tübingen
Lisa Licitra
Lisa Licitra University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always require a traditional medical school route. Prospective students have a variety of related online degrees and career pathways to choose from, which offer flexibility and different entry points into the healthcare industry.

For those interested in the administrative and business side of healthcare, a healthcare administration online degree can provide vital management skills and open doors to a wide range of roles in hospitals, clinics, and insurance companies.

Individuals looking to start working quickly may consider medical billing and coding schools with financial aid, which prepare students for in-demand jobs that ensure the accuracy and privacy of healthcare records.

If your passion is direct patient care, there are nursing school that does not require teas test options, allowing you to bypass some typical admissions exams. For current nurses looking to advance, asn to nurse practitioner programs offer bridge programs to higher clinical roles.

These alternative pathways provide flexible, accessible options for entering or advancing in the healthcare field—no matter your background or previous experience.

Best Scientists Citing Ulrich Keilholz

Trending Scientists